Can Roche’s #1 Therapeutic Area With $28 Billion In Revenue Grow Further?

By Trefis Team, Contributor Roche Holding’s (NASDAQ:RHHBY) oncology portfolio is its largest therapeutic area and it will likely remain flat with revenues of around $29 billion over the next few years, as growth in sales of newer drugs, such as Kadcyla, Tecentriq, and Alecensa will be offset by the decline expected in Mab… …read more

Read more here::